1-18 of 18
Kathy D. Miller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cytochrome P450 Oxidoreductase (POR) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103

Fei Shen, Guanglong Jiang, Santosh Philips, Laura Gardner, Gloria Xue, Erica Cantor, Reynold C. Ly, Wilberforce Osei, Xi Wu, Chau Dang, Donald Northfelt, Todd Skaar, Kathy D. Miller, George W. Sledge, Bryan P. Schneider
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (13): 2494–2500.
https://doi.org/10.1158/1078-0432.CCR-22-2431
Published: 05 July 2023
View article titled, Cytochrome P450 Oxidoreductase (<em>POR</em>) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103
Open the PDF for Cytochrome P450 Oxidoreductase (<em>POR</em>) Associated with Severe Paclitaxel-Induced Peripheral Neuropathy in Patients of European Ancestry from ECOG-ACRIN E5103 in another window
Includes: Supplementary data
Journal Articles

Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

Milan Radovich, Jeffrey P. Solzak, Chao J. Wang, Bradley A. Hancock, Sunil Badve, Sandra K. Althouse, Steven M. Bray, Anna Maria V. Storniolo, Tarah J. Ballinger, Bryan P. Schneider, Kathy D. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3235–3241.
https://doi.org/10.1158/1078-0432.CCR-21-3078
Published: 02 August 2022
View article titled, Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
Open the PDF for Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze, Mary D. Chamberlin, Barbara J. Haley, Anna Maria V. Storniolo, Mridula P. Reddy, Scott A. Anderson, Collin T. Zimmerman, Anne P. O'Dea, Hamid R. Mirshahidi, Jordi Rodon Ahnert, Frank J. Brescia, Olwen Hahn, Jane M. Raymond, David D. Biggs, Roisin M. Connolly, Elad Sharon, Larissa A. Korde, Robert J. Gray, Edward Mayerson, Melissa Plets, Charles D. Blanke, Young Kwang Chae, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 271–278.
https://doi.org/10.1158/1078-0432.CCR-21-2182
Published: 19 January 2022
View article titled, A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Open the PDF for A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609) in another window
Includes: Supplementary data
Journal Articles

Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC

Sagar D. Sardesai, Alexandra Thomas, Christopher Gallagher, Filipa Lynce, Yvonne Lynn Ottaviano, Tarah Jean Ballinger, Bryan P. Schneider, Anna Maria Storniolo, Amber Bauchle, Sandra K. Althouse, Susan M. Perkins, Andrea R. Masters, Robert E. Stratford, Jr, Zizheng Dong, Jing-Yuan Liu, Jian-Ting Zhang, Kathy D. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5810–5817.
https://doi.org/10.1158/1078-0432.CCR-21-0493
Published: 01 November 2021
View article titled, Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC
Open the PDF for Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC in another window
Journal Articles

Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer

Heather A. Parsons, Justin Rhoades, Sarah C. Reed, Gregory Gydush, Priyanka Ram, Pedro Exman, Kan Xiong, Christopher C. Lo, Tianyu Li, Mark Fleharty, Gregory J. Kirkner, Denisse Rotem, Ofir Cohen, Fangyan Yu, Mariana Fitarelli-Kiehl, Ka Wai Leong, Melissa E. Hughes, Shoshana M. Rosenberg, Laura C. Collins, Kathy D. Miller, Brendan Blumenstiel, Lorenzo Trippa, Carrie Cibulskis, Donna S. Neuberg, Matthew DeFelice, Samuel S. Freeman, Niall J. Lennon, Nikhil Wagle, Gavin Ha, Daniel G. Stover, Atish D. Choudhury, Gad Getz, Eric P. Winer, Matthew Meyerson, Nancy U. Lin, Ian Krop, J. Christopher Love, G. Mike Makrigiorgos, Ann H. Partridge, Erica L. Mayer, Todd R. Golub, Viktor A. Adalsteinsson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2556–2564.
https://doi.org/10.1158/1078-0432.CCR-19-3005
Published: 01 June 2020
View article titled, Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Open the PDF for Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer in another window
Includes: Supplementary data
Journal Articles

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations

Nicholas Pulliam, Fang Fang, Ali R. Ozes, Jessica Tang, Adeoluwa Adewuyi, Harold Keer, John Lyons, Stephen B. Baylin, Daniela Matei, Harikrishna Nakshatri, Feyruz V. Rassool, Kathy D. Miller, Kenneth P. Nephew
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (13): 3163–3175.
https://doi.org/10.1158/1078-0432.CCR-18-0204
Published: 01 July 2018
View article titled, An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations
Open the PDF for An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations in another window
Includes: Supplementary data
Journal Articles

64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer

Helen Lee, Anthony F. Shields, Barry A. Siegel, Kathy D. Miller, Ian Krop, Cynthia X. Ma, Patricia M. LoRusso, Pamela N. Munster, Karen Campbell, Daniel F. Gaddy, Shannon C. Leonard, Elena Geretti, Stephanie J. Blocker, Dmitri B. Kirpotin, Victor Moyo, Thomas J. Wickham, Bart S. Hendriks
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4190–4202.
https://doi.org/10.1158/1078-0432.CCR-16-3193
Published: 01 August 2017
View article titled, <sup>64</sup>Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Open the PDF for <sup>64</sup>Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure

Bryan P. Schneider, Fei Shen, Laura Gardner, Milan Radovich, Lang Li, Kathy D. Miller, Guanglong Jiang, Dongbing Lai, Anne O'Neill, Joseph A. Sparano, Nancy E. Davidson, David Cameron, Irmina Gradus-Pizlo, Ronald A. Mastouri, Thomas M. Suter, Tatiana Foroud, George W. Sledge, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1): 43–51.
https://doi.org/10.1158/1078-0432.CCR-16-0908
Published: 02 January 2017
View article titled, Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure
Open the PDF for Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure in another window
Includes: Supplementary data
Journal Articles

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199

Bryan P. Schneider, Lang Li, Milan Radovich, Fei Shen, Kathy D. Miller, David A. Flockhart, Guanglong Jiang, Gail Vance, Laura Gardner, Matteo Vatta, Shaochun Bai, Dongbing Lai, Daniel Koller, Fengmin Zhao, Anne O'Neill, Mary Lou Smith, Elda Railey, Carol White, Ann Partridge, Joseph Sparano, Nancy E. Davidson, Tatiana Foroud, George W. Sledge, Jr
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (22): 5082–5091.
https://doi.org/10.1158/1078-0432.CCR-15-0586
Published: 12 November 2015
View article titled, Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Open the PDF for Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 in another window
Includes: Supplementary data
Journal Articles

Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial

Bryan P. Schneider, Robert J. Gray, Milan Radovich, Fei Shen, Gail Vance, Lang Li, Guanglong Jiang, Kathy D. Miller, Julie R. Gralow, Maura N. Dickler, Melody A. Cobleigh, Edith A. Perez, Tamara N. Shenkier, Kirsten Vang Nielsen, Sven Müller, Ann Thor, George W. Sledge, Jr, Joseph A. Sparano, Nancy E. Davidson, Sunil S. Badve
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1281–1289.
https://doi.org/10.1158/1078-0432.CCR-12-3029
Published: 03 March 2013
View article titled, Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial
Open the PDF for Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial in another window
Includes: Supplementary data
Journal Articles

Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

Adrian M. Jubb, Kathy D. Miller, Hope S. Rugo, Adrian L. Harris, Dafeng Chen, James D. Reimann, Melody A. Cobleigh, Maike Schmidt, Virginia K. Langmuir, Kenneth J. Hillan, Daniel S. Chen, Hartmut Koeppen
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (2): 372–381.
https://doi.org/10.1158/1078-0432.CCR-10-1791
Published: 16 January 2011
View article titled, Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
Open the PDF for Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer

Bryan P. Schneider, Milan Radovich, Kathy D. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (17): 5297–5302.
https://doi.org/10.1158/1078-0432.CCR-08-2576
Published: 31 August 2009
View article titled, The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer
Open the PDF for The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer in another window
Journal Articles

Clinical-Translational Approaches to the Nm23-H1 Metastasis Suppressor

Patricia S. Steeg, Christine E. Horak, Kathy D. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (16): 5006–5012.
https://doi.org/10.1158/1078-0432.CCR-08-0238
Published: 12 August 2008
View article titled, Clinical-Translational Approaches to the Nm23-H1 Metastasis Suppressor
Open the PDF for Clinical-Translational Approaches to the Nm23-H1 Metastasis Suppressor in another window
Journal Articles

Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer

Amelia E. Hochreiter, Hongling Xiao, Erin M. Goldblatt, Sergei M. Gryaznov, Kathy D. Miller, Sunil Badve, George W. Sledge, Brittney-Shea Herbert
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (10): 3184–3192.
https://doi.org/10.1158/1078-0432.CCR-05-2760
Published: 17 May 2006
View article titled, Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer
Open the PDF for Telomerase Template Antagonist GRN163L Disrupts Telomere Maintenance, Tumor Growth, and Metastasis of Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Physiologic Imaging Pilot Study of Breast Cancer Treated with AZD2171

Kathy D. Miller, Michael Miller, Sanjana Mehrotra, Beamon Agarwal, Bruce H. Mock, Qi-Huang Zheng, Sunil Badve, Gary D. Hutchins, George W. Sledge, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (1): 281–288.
https://doi.org/10.1158/1078-0432.CCR-05-0219
Published: 05 January 2006
View article titled, A Physiologic Imaging Pilot Study of Breast Cancer Treated with AZD2171
Open the PDF for A Physiologic Imaging Pilot Study of Breast Cancer Treated with AZD2171 in another window
Journal Articles

The Potential and Suitability of 2-Methoxyestradiol in Cancer Therapy

Carolyn Sidor, Robert D'Amato, Kathy D. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 6094–6096.
https://doi.org/10.1158/1078-0432.CCR-05-0724
Published: 22 August 2005
View article titled, The Potential and Suitability of 2-Methoxyestradiol in Cancer Therapy
Open the PDF for The Potential and Suitability of 2-Methoxyestradiol in Cancer Therapy in another window
Journal Articles

A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer

Kathy D. Miller, Jose Manuel Trigo, Catherine Wheeler, Alan Barge, Jacqui Rowbottom, George Sledge, Jose Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3369–3376.
https://doi.org/10.1158/1078-0432.CCR-04-1923
Published: 02 May 2005
View article titled, A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer
Open the PDF for A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer in another window
Journal Articles

A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer

Kathy D. Miller, Thomas J. Saphner, David M. Waterhouse, T.-T. Chen, Anita Rush-Taylor, Joseph A. Sparano, Antonio C. Wolff, Melody A. Cobleigh, Susan Galbraith, George W. Sledge
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (6): 1971–1975.
https://doi.org/10.1158/1078-0432.CCR-03-0968
Published: 24 March 2004
View article titled, A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer
Open the PDF for A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer in another window